Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Wien Med Wochenschr ; 172(11-12): 268-273, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34613520

RESUMEN

BACKGROUND: Gastrointestinal tuberculosis (TB) is a rare manifestation in low TB-incidence countries such as Austria. It is usually seen in immunocompromised patients or in migrants being more susceptible for extrapulmonary disease manifestations. CASE DESCRIPTION: We report a very rare manifestation of severe gastrointestinal TB in a 49-year-old previously healthy man from Upper Austria. Endoscopy showed a large tumor mass obstructing about 2/3 of the lumen of the cecum. Positron emission tomography/computed tomography scan revealed not only a high metabolic activity in the tumor mass, but also active pulmonary lesions in both upper lung lobes. Bronchial secretion showed acid-fast bacilli in the microscopy and polymerase chain reaction was positive for M. tuberculosis complex. Phenotypic resistance testing showed no resistance for first-line anti-TB drugs. Treatment with isoniazid, rifampicin, pyrazinamide and ethambutol was initiated. Based on therapeutic drug monitoring, the standard treatment regime was adapted to rifampicin high dose. TB treatment was well tolerated and the patient achieved relapse-free cure one year after the end of treatment. CONCLUSION: Gastrointestinal involvement mimicking an intestinal tumor is a very rare TB manifestation in previously healthy Austrians. However, it should be kept in mind due to increasing migration from countries with higher rates of extrapulmonary TB and due to an increasing number of immunocompromised patients. TB telephone consultations can support medical professionals in the diagnosis and the management of complex TB patients. TB management is currently at a transitional stage from a programmatic to personalized management concept including therapeutic drug monitoring or biomarker-guided treatment duration to achieve relapse-free cure.


Asunto(s)
Neoplasias Gastrointestinales , Mycobacterium tuberculosis , Austria , Neoplasias Gastrointestinales/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Rifampin/uso terapéutico
2.
Open Res Eur ; 1: 82, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-37645126

RESUMEN

Background: Ethyl lactate is an environmentally benign solvent, which could substitute petrol-based volatile organic compounds (VOCs) in many applications if production costs are reduced. It is usually produced by the esterification of lactic acid with ethanol - two important chemical building blocks of biorefineries that are available at industrial scale. Reactive distillation is a promising alternative production process, which utilises process intensification to increase energy efficiency and space-time yield by enhancing the reaction kinetics. Methods: In this work, process intensification of ethyl lactate production by means of distillation was analysed with special focus on the efficient separation of water. Different setups were evaluated. The feedstock requirements were studied and the process was optimized regarding reaction kinetics in experiments on laboratory level. The preparation of anhydrous starting mixtures for ethyl lactate formation was tested in batch experiments and applied to reactive distillation. The simultaneous distillation was optimized and assessed for its energy efficiency. For this purpose, integrated reactive distillation was compared to a simple setup for distillation enhanced esterification. Results: It was found that an optimized serial setup of reactors and distillation steps can offer similar process intensification at a lower distillate rate compared to simultaneous reactive distillation and is therefore more energy efficient. Moreover, the serial setup is more flexible and straight-forward to regulate and scale-up. Conclusions: Based on the experimental results, the optimal setup and parameters of a continuous process for ethyl lactate production by distillation enhanced esterification was presented.

3.
Emerg Infect Dis ; 26(11): 2776-2778, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-33079051

RESUMEN

The clinical relevance of newly described nontuberculous mycobacteria is often unclear. We report a case of pulmonary infection caused by Mycobacterium hassiacum in an immunocompetent patient in Austria who had chronic obstructive pulmonary disease. Antimicrobial drug susceptibility testing showed low MICs for macrolides, aminoglycosides, fluoroquinolones, tetracyclines, imipenem, and linezolid.


Asunto(s)
Enfermedades Pulmonares , Mycobacteriaceae , Infecciones por Mycobacterium no Tuberculosas , Austria , Humanos , Enfermedades Pulmonares/diagnóstico , Enfermedades Pulmonares/tratamiento farmacológico , Enfermedades Pulmonares/microbiología , Pruebas de Sensibilidad Microbiana , Mycobacteriaceae/efectos de los fármacos , Infecciones por Mycobacterium no Tuberculosas/diagnóstico , Infecciones por Mycobacterium no Tuberculosas/tratamiento farmacológico
4.
Clin Nucl Med ; 41(4): e187-94, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26704732

RESUMEN

PURPOSE: The aim of this retrospective study was to assess the value of 18F-FDG PET/CT in the initial evaluation and follow-up of patients with tuberculosis (TB). PATIENTS AND METHODS: Thirty-five patients (18 men) with pulmonary or extrapulmonary TB were included. Diagnosis of TB was based either on histology or microbiological assessment in 32 patients and was based on typical morphological features of TB in CT and improvement on antimycobacterial medication in 3 patients. Eighty-eight 18F-FDG PET/CT scans were performed at initial assessment and during treatment, on a Siemens Biograph PET/CT. Diagnostic contrast-enhanced CT scans were performed on the 40-slice multidetector CT of the PET/CT scanner. Mean (SD) anti-TB treatment duration was 16.1 (8.9) months. RESULTS: The initial 18F-FDG PET identified 64 affected regions in 34 among 35 patients, whereas CT identified 34 affected organs in 23 patients. Matching image results between PET and CT were observed at first visit in 11 patients (31.4%), with relevant differences in 23 (65.7%). In 1 patient, both modalities remained negative. During follow-up 18F-FDG PET scans, we recorded 15 cases with remission of disease, 16 with residual disease (2 patients with multidrug-resistant infection), and 4 cases with progressive disease or delayed onset of adequate immunological response. In only 3 patients, both modalities, PET and CT, showed completely equivalent results. CONCLUSIONS: Both components of 18F-FDG PET/CT provide complementary information at initial evaluation and during follow-up; however, 18F-FDG showed more abnormal findings than CT. 18F-FDG PET/CT might be useful for the establishment of individualized treatment regimes, but this requires further prospective studies.


Asunto(s)
Imagen Multimodal , Tomografía de Emisión de Positrones , Tomografía Computarizada por Rayos X , Tuberculosis/diagnóstico por imagen , Adolescente , Adulto , Anciano , Femenino , Fluorodesoxiglucosa F18 , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Radiofármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA